Eli Lilly and Company, a global pharmaceutical leader, announced plans to launch its blockbuster weight-loss drug Mounjaro (tirzepatide) in emerging markets by…
Key Highlights What is Liraglutide? Liraglutide is a GLP-1 receptor agonist, a class of medications revolutionizing type 2 diabetes treatment…
The $1.5 Trillion Weight Loss Economy of 2030: A Breakdown of the Market Reshaping Health By 2030, the global weight…
The fight against obesity is entering an exciting new era. With blockbuster drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) already…
Key Highlights: A New Hope for Obesity and Diabetes Obesity and type 2 diabetes (T2D) are global health crises, affecting 1…
